Cytomegalovirus disease in children with acute lymphoblastic leukemia

Area of Science:

• Pediatric Oncology
• Infectious Diseases
• Hematology

Background:

• Viral infections, particularly cytomegalovirus (CMV), are often overlooked in pediatric acute lymphoblastic leukemia (ALL) patients receiving chemotherapy.
• High CMV seroprevalence in regions like India suggests it's a critical pathogen causing fever, cytopenia, and end-organ damage in this population.
• Limited data exist on CMV disease incidence and presentation in pediatric ALL.

Purpose of the Study:

• To prospectively evaluate the incidence and clinical manifestations of CMV disease in children with ALL and prolonged febrile neutropenia (FN).
• To assess the role of CMV as a pathogen in pediatric ALL patients experiencing prolonged FN or end-organ damage.
• To identify factors associated with CMV infection and recurrence in this cohort.

Main Methods:

• Prospective assessment of pediatric ALL patients with prolonged FN over 3 years for CMV disease.
• Evaluation of patients with end-organ damage (pneumonia, retinitis, colitis) for CMV involvement.
• Utilized quantitative and qualitative PCR from various samples (blood, body fluids, tissue) and ophthalmologic examinations.

Main Results:

• CMV disease was detected in 10% of pediatric ALL patients with prolonged FN.
• CMV infection was also identified in patients with end-organ damage, commonly affecting the lungs and eyes.
• CMV reactivation frequently occurred during less intensive chemotherapy phases; prolonged lymphopenia correlated with infection relapse.

Conclusions:

• Cytomegalovirus is a significant pathogen in children undergoing standard chemotherapy for ALL.
• Early diagnosis and targeted antiviral therapy, such as parenteral ganciclovir for 14-21 days, lead to favorable outcomes and prevent recurrence.
• Monitoring for CMV is crucial in pediatric ALL patients, especially those with prolonged FN or lymphopenia.